NEW YORK – The Centers for Medicare & Medicaid Services proposal to alter its 14-day rule has laboratories worried that key exemptions gained through a 2018 revision of the rule may be in danger.
Debate over the CMS proposal has also highlighted a divide on this issue between smaller molecular pathology outfits and large reference labs, with the former generally advocating for the rule to remain unchanged and the latter advocating for the addition of a provision they believe could reduce some administrative burdens associated with the rule.